Developer docs
API playgroundTry for free, no card

Search company profiles

Gyre Therapeutics

Full company profile

uuid0002eyd

Namestring
Gyre Therapeutics
Legal namestring
Gyre Therapeutics, Inc.
Websiteurl
gyretx.com
Company typeenum
Public
Founded yearint
1997
Descriptiontext

Gyre Therapeutics is a publicly-traded (NASDAQ: GYRE) commercial-stage biopharmaceutical company headquartered in San Diego, California, with operations in both the United States and China through its majority-owned subsidiary Gyre Pharmaceuticals. The company focuses on organ fibrosis and inflammatory diseases, with a portfolio centered on small-molecule anti-fibrotic therapeutics. Its flagship approved product, ETUARY (pirfenidone capsule), was the first treatment approved for idiopathic pulmonary fibrosis (IPF) in China in 2011 and generated $116.6 million in FY2025 revenue, representing 10% year-over-year growth. The company distributes ETUARY and pipeline products in China through Gyre Pharmaceuticals, primarily reaching hospitals and specialty pharmacies via direct enterprise sales.

Gyre's lead development candidate is F351 (hydronidone), a structurally modified derivative of pirfenidone targeting the TGF-β1 signaling pathway, being developed for chronic hepatitis B (CHB)-induced liver fibrosis in China and MASH-associated liver fibrosis in the United States. The China NMPA granted priority review status in March 2026 and accepted the New Drug Application in May 2026, with potential first-in-class approval positioning. Additional pipeline assets include F528 (a non-antibacterial macrolide immunomodulator for COPD), CG923308 (a CDK2-cyclin E dual degrader for cancer), and CG620953 (a TYK2-JAK1 dual degrader for autoimmune diseases). The May 2026 acquisition of Cullgen Inc. for approximately $300 million in an all-stock transaction added Targeted Protein Degradation (TPD) and Degrader-Antibody Conjugate (DAC) platforms, enabling pursuit of traditionally undruggable targets.

The company's revenue model is anchored in pharmaceutical product sales of ETUARY in China. Its go-to-market is enterprise field sales through the China subsidiary to hospitals and specialty pharmacies. Future revenue is expected to come from approved indications of pipeline products (F351, F528) and additional indications like pneumoconiosis, where a Phase 3 trial completed enrollment in 2025 with 272 patients across 18 centers. Pricing details are not publicly disclosed; standard pharmaceutical pricing applies through regulatory and market channels. The company raised approximately $19.8 million via a post-IPO secondary offering in May 2025 and is profitable at the quarterly level, with Q3 2025 net income of $5.9 million on $30.6 million in revenue.

Short descriptiontext

Gyre Therapeutics is a commercial-stage biopharmaceutical company developing anti-fibrotic and inflammatory disease therapeutics, with the approved product ETUARY (pirfenidone) for IPF in China and a pipeline including F351 for liver fibrosis, supported by protein degradation platforms acquired from Cullgen.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharmaceutical therapeutics, organ fibrosis treatments, anti-fibrotic drugs, targeted protein degradation, inflammatory disease therapies
Industry4 codes
PRIMARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Product Sales (Pharmaceuticals)
TypeHardware Sales
Description

Gyre generates revenue through the sale of approved pharmaceutical products, primarily ETUARY (pirfenidone capsule) which was the first approved treatment for idiopathic pulmonary fibrosis in China in 2011. Revenue grew 10% to $116.6 million in FY 2025.

biospace.com
2Pipeline Development
TypeLicensing Royalties
Description

The company is advancing clinical-stage pipeline candidates including F351 (Hydronidone) for liver fibrosis, with NDA accepted by China's NMPA. Future revenue potential from new drug approvals.

biospace.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1ETUARY
Description

Pirfenidone capsule - first approved treatment for idiopathic pulmonary fibrosis (IPF) in the People's Republic of China, approved in 2011

gyretx.com
+2 more records
Core offering1 text field

Gyre Therapeutics is a commercial-stage biopharmaceutical company developing and commercializing small-molecule therapeutics for organ fibrosis, inflammatory diseases, and cancer. Its flagship approved product, ETUARY (pirfenidone capsule), was the first treatment approved for idiopathic pulmonary fibrosis in China (2011). The pipeline includes F351 (Hydronidone) for liver fibrosis, F528 for COPD, and dual protein degraders (CG923308 for oncology, CG620953 for autoimmune diseases) developed via Targeted Protein Degradation and Degrader-Antibody Conjugate platforms acquired through Cullgen.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Statistically significant fibrosis regression after 52 weeks of F351 treatment in CHB patients
+3 more records
Product overview1 text field

Gyre Therapeutics is a commercial-stage biopharmaceutical company offering a portfolio of small-molecule therapeutics focused on organ fibrosis and inflammatory diseases. The company's core products include ETUARY™ (pirfenidone capsule) as its flagship approved product for IPF in China, and F351 (Hydronidone) as the lead development candidate for liver fibrosis across multiple indications. The pipeline spans F528 for COPD, CDK2-Cyclin E dual degrader (CG923308) for cancers, and TYK2-JAK1 dual degrader (CG620953) for autoimmune diseases. The May 2024 acquisition of Cullgen expanded capabilities with targeted protein degradation (TPD) and degrader-antibody conjugate (DAC) technology platforms.

Product and service5 records
1ETUARY (pirfenidone capsule)
CategoryApproved pharmaceutical product
Description

The first approved treatment for idiopathic pulmonary fibrosis (IPF) in the People's Republic of China, approved in 2011. Sold to hospitals and specialty pharmacies in China through the majority-owned subsidiary Gyre Pharmaceuticals for the treatment of IPF patients.

2F351 (Hydronidone)
CategoryClinical-stage therapeutic candidate
Description

A structurally modified derivative of pirfenidone targeting the TGF-β1 signaling pathway for treatment of liver fibrosis. Lead development candidate for chronic hepatitis B (CHB)-associated liver fibrosis in China and MASH-associated liver fibrosis in the United States. NDA accepted by China's NMPA in May 2026.

3F528
CategoryPreclinical therapeutic candidate
Description

A novel non-antibacterial macrolide discovered through rational design strategy to eliminate antibacterial activity while preserving immunomodulatory properties for treatment of chronic obstructive pulmonary disease (COPD). Designed to address airway inflammation without antibiotic resistance risk.

4CG923308 (CDK2-Cyclin E Dual Degrader)
CategoryPreclinical oncology candidate
Description

A highly potent and selective dual degrader of CDK2 and cyclin E developed through targeted protein degradation technology. Targets cyclin E amplification and CDK4/6 inhibitor resistance in ovarian, endometrial, gastroesophageal, breast, and lung cancers.

5CG620953 (TYK2-JAK1 Dual Degrader)
CategoryPreclinical autoimmune candidate
Description

A highly potent and selective dual degrader of TYK2 and JAK1 targeting inflammatory pathways in systemic lupus erythematosus, rheumatoid arthritis, and inflammatory bowel disease.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-03
Description

Gyre Therapeutics agreed to acquire Cullgen Inc., a privately-held clinical-stage biopharmaceutical company focused on targeted protein degrader and degrader-antibody conjugate (DAC) therapies for inflammatory diseases and cancer, in an all-stock transaction valued at approximately $300 million. Cullgen became a wholly-owned subsidiary of Gyre, creating a fully integrated biopharma company with U.S.- and China-based capabilities spanning discovery through commercialization. The acquisition was completed on May 4, 2026.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Madrigal commercializes Rezdiffra, the first FDA-approved treatment for MASH — directly competing with Gyre's F351 in the MASH-associated liver fibrosis indication that Gyre plans to pursue in the US.

TypeDirect peer
Description

Clinical-stage biopharma focused on fibrosis (previously developed pamrevlumab for IPF and other fibrotic conditions) with comparable therapeutic focus on organ fibrosis and pipeline-stage assets targeting similar indications to Gyre's F351 and ETUARY.

TypeDirect peer
Description

Clinical-stage biopharma developing integrin-targeted therapies for fibrosis (IPF and other fibrotic diseases), with similar therapeutic focus on fibrogenesis pathways to Gyre's TGF-β1-targeted approach.

TypeBroad incumbent
Description

Established biopharma with commercial franchise in pulmonary hypertension and IPF (Tyvaso, Orenitram) — overlapping pulmonology indication with Gyre's ETUARY and F528, though United Therapeutics is a much larger, multi-product commercial-stage company.

5Boehringer Ingelheim (Ofev)
TypeBroad incumbent
Description

Markets Ofev (nintedanib), the global standard-of-care for IPF alongside Roche's Esbriet (pirfenidone) — directly competitive with Gyre's ETUARY (pirfenidone) globally, though Boehringer operates as a much larger diversified pharma.

TypeDirect peer
Description

Pioneer in targeted protein degradation (PROTAC technology) with clinical-stage oncology and neuroscience assets — directly comparable to Gyre's Cullgen-acquired TPD platform, though Arvinas is more advanced in clinical development.

TypeDirect peer
Description

Clinical-stage biotech developing heterobifunctional protein degraders across immunology and oncology — overlapping modality and target space with Cullgen's TYK2-JAK1 and CDK2-cyclin E degrader programs now under Gyre.

TypeDirect peer
Description

Focused on liver diseases including MASH/NASH with obeticholic acid development — comparable focus on chronic liver fibrosis indications where Gyre's F351 (Hydronidone) is positioned.

TypeEmerging player
Description

Clinical-stage biotech leveraging targeted protein degradation with partnered programs (including with Sanofi) — comparable TPD modality to Cullgen's platform though with different target focus and deeper pharma partnerships.

TypeRegional player
Description

France-based biopharma focused on MASH and liver diseases — comparable therapeutic focus on MASH-driven fibrosis though operating primarily in European markets, providing regional competition if Gyre's F351 seeks global development.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment7 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles19 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds15 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors24 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Gyre Therapeutics

Biopharmaceuticalsgyretx.com

Gyre Therapeutics is a commercial-stage biopharmaceutical company developing anti-fibrotic and inflammatory disease therapeutics, with the approved product ETUARY (pirfenidone) for IPF in China and a pipeline including F351 for liver fibrosis, supported by protein degradation platforms acquired from Cullgen.

What Gyre Therapeutics does

Gyre Therapeutics is a publicly-traded (NASDAQ: GYRE) commercial-stage biopharmaceutical company headquartered in San Diego, California, with operations in both the United States and China through its majority-owned subsidiary Gyre Pharmaceuticals. The company focuses on organ fibrosis and inflammatory diseases, with a portfolio centered on small-molecule anti-fibrotic therapeutics. Its flagship approved product, ETUARY (pirfenidone capsule), was the first treatment approved for idiopathic pulmonary fibrosis (IPF) in China in 2011 and generated $116.6 million in FY2025 revenue, representing 10% year-over-year growth. The company distributes ETUARY and pipeline products in China through Gyre Pharmaceuticals, primarily reaching hospitals and specialty pharmacies via direct enterprise sales.

Gyre's lead development candidate is F351 (hydronidone), a structurally modified derivative of pirfenidone targeting the TGF-β1 signaling pathway, being developed for chronic hepatitis B (CHB)-induced liver fibrosis in China and MASH-associated liver fibrosis in the United States. The China NMPA granted priority review status in March 2026 and accepted the New Drug Application in May 2026, with potential first-in-class approval positioning. Additional pipeline assets include F528 (a non-antibacterial macrolide immunomodulator for COPD), CG923308 (a CDK2-cyclin E dual degrader for cancer), and CG620953 (a TYK2-JAK1 dual degrader for autoimmune diseases). The May 2026 acquisition of Cullgen Inc. for approximately $300 million in an all-stock transaction added Targeted Protein Degradation (TPD) and Degrader-Antibody Conjugate (DAC) platforms, enabling pursuit of traditionally undruggable targets.

The company's revenue model is anchored in pharmaceutical product sales of ETUARY in China. Its go-to-market is enterprise field sales through the China subsidiary to hospitals and specialty pharmacies. Future revenue is expected to come from approved indications of pipeline products (F351, F528) and additional indications like pneumoconiosis, where a Phase 3 trial completed enrollment in 2025 with 272 patients across 18 centers. Pricing details are not publicly disclosed; standard pharmaceutical pricing applies through regulatory and market channels. The company raised approximately $19.8 million via a post-IPO secondary offering in May 2025 and is profitable at the quarterly level, with Q3 2025 net income of $5.9 million on $30.6 million in revenue.

Gyre Therapeutics firmographics

Firmographics
Name
Gyre Therapeutics
Legal name
Gyre Therapeutics, Inc.
Website
https://gyretx.com
Company type
Public
Founded year
1997
Operating status
Operating
Headcount range
1–10 employees
Short description
Gyre Therapeutics is a commercial-stage biopharmaceutical company developing anti-fibrotic and inflammatory disease therapeutics, with the approved product ETUARY (pirfenidone) for IPF in China and a pipeline including F351 for liver fibrosis, supported by protein degradation platforms acquired from Cullgen.
Ownership category
akta.pro rank

Gyre Therapeutics industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Biopharmaceutical therapeutics
  • Organ fibrosis treatments
  • Anti-fibrotic drugs
  • Targeted protein degradation
  • Inflammatory disease therapies

Where Gyre Therapeutics is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Gyre Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Product Sales (Pharmaceuticals): Gyre generates revenue through the sale of approved pharmaceutical products, primarily ETUARY (pirfenidone capsule) which was the first approved treatment for idiopathic pulmonary fibrosis in China in 2011. Revenue grew 10% to $116.6 million in FY 2025.
  2. Pipeline Development: The company is advancing clinical-stage pipeline candidates including F351 (Hydronidone) for liver fibrosis, with NDA accepted by China's NMPA. Future revenue potential from new drug approvals.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Gyre Therapeutics product offering

Product offering

Core offering

Gyre Therapeutics is a commercial-stage biopharmaceutical company developing and commercializing small-molecule therapeutics for organ fibrosis, inflammatory diseases, and cancer. Its flagship approved product, ETUARY (pirfenidone capsule), was the first treatment approved for idiopathic pulmonary fibrosis in China (2011). The pipeline includes F351 (Hydronidone) for liver fibrosis, F528 for COPD, and dual protein degraders (CG923308 for oncology, CG620953 for autoimmune diseases) developed via Targeted Protein Degradation and Degrader-Antibody Conjugate platforms acquired through Cullgen.

Product overview

Gyre Therapeutics is a commercial-stage biopharmaceutical company offering a portfolio of small-molecule therapeutics focused on organ fibrosis and inflammatory diseases. The company's core products include ETUARY™ (pirfenidone capsule) as its flagship approved product for IPF in China, and F351 (Hydronidone) as the lead development candidate for liver fibrosis across multiple indications. The pipeline spans F528 for COPD, CDK2-Cyclin E dual degrader (CG923308) for cancers, and TYK2-JAK1 dual degrader (CG620953) for autoimmune diseases. The May 2024 acquisition of Cullgen expanded capabilities with targeted protein degradation (TPD) and degrader-antibody conjugate (DAC) technology platforms.

Differentiator

Problem solved

Functional benefit

Brands

  • ETUARY: Pirfenidone capsule - first approved treatment for idiopathic pulmonary fibrosis (IPF) in the People's Republic of China, approved in 2011
  • F351 (Hydronidone)
  • F528

Products and services

  • ETUARY (pirfenidone capsule) The first approved treatment for idiopathic pulmonary fibrosis (IPF) in the People's Republic of China, approved in 2011. Sold to hospitals and specialty pharmacies in China through the majority-owned subsidiary Gyre Pharmaceuticals for the treatment of IPF patients.
  • F351 (Hydronidone) A structurally modified derivative of pirfenidone targeting the TGF-β1 signaling pathway for treatment of liver fibrosis. Lead development candidate for chronic hepatitis B (CHB)-associated liver fibrosis in China and MASH-associated liver fibrosis in the United States. NDA accepted by China's NMPA in May 2026.
  • F528 A novel non-antibacterial macrolide discovered through rational design strategy to eliminate antibacterial activity while preserving immunomodulatory properties for treatment of chronic obstructive pulmonary disease (COPD). Designed to address airway inflammation without antibiotic resistance risk.
  • CG923308 (CDK2-Cyclin E Dual Degrader) A highly potent and selective dual degrader of CDK2 and cyclin E developed through targeted protein degradation technology. Targets cyclin E amplification and CDK4/6 inhibitor resistance in ovarian, endometrial, gastroesophageal, breast, and lung cancers.
  • CG620953 (TYK2-JAK1 Dual Degrader) A highly potent and selective dual degrader of TYK2 and JAK1 targeting inflammatory pathways in systemic lupus erythematosus, rheumatoid arthritis, and inflammatory bowel disease.

Quantifiable outcome

  • Statistically significant fibrosis regression after 52 weeks of F351 treatment in CHB patients
  • +3 more outcomes

Companies that use Gyre Therapeutics

Customer profile

Segments7 records

Ideal customer profiles4 records

Gyre Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Gyre Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Cullgen Inc.coreStrategic or Co-development Partner · 3 March 2026Gyre Therapeutics agreed to acquire Cullgen Inc., a privately-held clinical-stage biopharmaceutical company focused on targeted protein degrader and degrader-antibody conjugate (DAC) therapies for inflammatory diseases and cancer, in an all-stock transaction valued at approximately $300 million. Cullgen became a wholly-owned subsidiary of Gyre, creating a fully integrated biopharma company with U.S.- and China-based capabilities spanning discovery through commercialization. The acquisition was completed on May 4, 2026.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Gyre Therapeutics competitors and assessment

Company assessment

Direct peers

  • Madrigal Pharmaceuticals: Madrigal commercializes Rezdiffra, the first FDA-approved treatment for MASH — directly competing with Gyre's F351 in the MASH-associated liver fibrosis indication that Gyre plans to pursue in the US.
  • FibroGen: Clinical-stage biopharma focused on fibrosis (previously developed pamrevlumab for IPF and other fibrotic conditions) with comparable therapeutic focus on organ fibrosis and pipeline-stage assets targeting similar indications to Gyre's F351 and ETUARY.
  • Pliant Therapeutics: Clinical-stage biopharma developing integrin-targeted therapies for fibrosis (IPF and other fibrotic diseases), with similar therapeutic focus on fibrogenesis pathways to Gyre's TGF-β1-targeted approach.
  • Arvinas: Pioneer in targeted protein degradation (PROTAC technology) with clinical-stage oncology and neuroscience assets — directly comparable to Gyre's Cullgen-acquired TPD platform, though Arvinas is more advanced in clinical development.
  • Kymera Therapeutics: Clinical-stage biotech developing heterobifunctional protein degraders across immunology and oncology — overlapping modality and target space with Cullgen's TYK2-JAK1 and CDK2-cyclin E degrader programs now under Gyre.
  • Intercept Pharmaceuticals: Focused on liver diseases including MASH/NASH with obeticholic acid development — comparable focus on chronic liver fibrosis indications where Gyre's F351 (Hydronidone) is positioned.

Broad incumbents

  • United Therapeutics: Established biopharma with commercial franchise in pulmonary hypertension and IPF (Tyvaso, Orenitram) — overlapping pulmonology indication with Gyre's ETUARY and F528, though United Therapeutics is a much larger, multi-product commercial-stage company.
  • Boehringer Ingelheim (Ofev): Markets Ofev (nintedanib), the global standard-of-care for IPF alongside Roche's Esbriet (pirfenidone) — directly competitive with Gyre's ETUARY (pirfenidone) globally, though Boehringer operates as a much larger diversified pharma.

Emerging players

  • Nurix Therapeutics: Clinical-stage biotech leveraging targeted protein degradation with partnered programs (including with Sanofi) — comparable TPD modality to Cullgen's platform though with different target focus and deeper pharma partnerships.

Regional players

  • GENFIT: France-based biopharma focused on MASH and liver diseases — comparable therapeutic focus on MASH-driven fibrosis though operating primarily in European markets, providing regional competition if Gyre's F351 seeks global development.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Gyre Therapeutics social profiles

Digital presence

Gyre Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Gyre Therapeutics leadership team

Management profile

Number of profiles

Profiles19 records

Gyre Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Gyre Therapeutics funding detail

Funding detail

Funding overview

Funding rounds15 records

Investors24 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Gyre Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gyre Therapeutics

What does Gyre Therapeutics do?

Gyre Therapeutics is a commercial-stage biopharmaceutical company developing and commercializing small-molecule therapeutics for organ fibrosis, inflammatory diseases, and cancer. Its flagship approved product, ETUARY (pirfenidone capsule), was the first treatment approved for idiopathic pulmonary fibrosis in China (2011). The pipeline includes F351 (Hydronidone) for liver fibrosis, F528 for COPD, and dual protein degraders (CG923308 for oncology, CG620953 for autoimmune diseases) developed via Targeted Protein Degradation and Degrader-Antibody Conjugate platforms acquired through Cullgen.

Is Gyre Therapeutics a public or private company?

Gyre Therapeutics is a public company. It is classified as public and is currently operating.

When was Gyre Therapeutics founded?

Gyre Therapeutics was founded in 1997. It employs 1 to 10 people.

Where is Gyre Therapeutics based?

Gyre Therapeutics is headquartered in South San Francisco, United States, in the North America region.

How does Gyre Therapeutics make money?

Two revenue lines are on record. Product Sales (Pharmaceuticals) is the primary driver. The others are pipeline Development.

Who are Gyre Therapeutics's main competitors?

Direct peers on record are Madrigal Pharmaceuticals, FibroGen, Pliant Therapeutics, Arvinas, Kymera Therapeutics and Intercept Pharmaceuticals. Broad incumbents are United Therapeutics and Boehringer Ingelheim (Ofev). Nurix Therapeutics is listed as an emerging player. GENFIT is listed as a regional player.

Does Gyre Therapeutics have an API?

No public API is recorded for Gyre Therapeutics.

What industry is Gyre Therapeutics in?

Gyre Therapeutics's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals, with a secondary code of HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceCoherus cuts 30% of staffers, Gyre makes post-acquisition layoffsCoherus Oncology is cutting 30% of its workforce, while Gyre Therapeutics is laying off an undisclosed number of employees after acquiring Cullgen. Coherus' cuts lower its quarterly core cash burn by $6 million, and Gyre's personnel costs rose $3.6 million in Q3 due to restructuring and severance.American Banking and Market NewsGyre Therapeutics (NASDAQ:GYRE) Stock Rating Raised to “Hold” at Wall Street ZenWall Street Zen raised Gyre Therapeutics from a sell to a hold rating. The company reported Q3 EPS of $0.04, beating estimates of -$0.15, with revenue of $32.93 million. Analysts expect a loss of $0.61 per share for the current year.MarketBeatGyre Therapeutics (GYRE) Expected to Announce Quarterly Earnings on FridayGyre Therapeutics is expected to report Q3 2026 earnings on Friday, November 6th, with analysts projecting a loss of $0.15 per share and revenue of $28.40 million. The company's average analyst rating is Reduce, with Wall Street Zen downgrading to Sell and Zacks upgrading to Hold.American Banking and Market NewsGyre Therapeutics (GYRE) Set to Post Earnings on FridayGyre Therapeutics is expected to report Q3 2026 earnings on Friday, November 6th, with analysts projecting a loss of $0.15 per share and revenue of $28.40 million. The company's stock opened at $6.41, and analysts have an average rating of 'Reduce'.Ticker ReportContrasting Theravance Biopharma (NASDAQ:TBPH) & Gyre Therapeutics (NASDAQ:GYRE)Theravance Biopharma and Gyre Therapeutics are compared on institutional ownership, analyst ratings, and financials. Theravance has 99.1% institutional ownership and a consensus price target of $19.40, while Gyre has 24% institutional ownership and a lower P/E ratio. Theravance beats Gyre on 10 of 13 factors.The future of tradingGyre Therapeutics Sets CEO Ying Luo’s Annual Base Salary at $500,000Gyre Therapeutics entered new employment agreements with CEO Ying Luo and CFO Thomas Eastling on October 16, 2026. Luo receives a $500,000 annual base salary with a $150,000 target bonus, while Eastling gets $339,066 with a $70,000 target. Termination or resignation triggers base salary paid over six months and partial equity vesting.TradingViewGyre Therapeutics signs new employment agreements with CEO Ying Luo and CFO Thomas EastlingGyre Therapeutics signed new employment agreements with CEO Ying Luo and CFO Thomas Eastling, effective October 16, 2026. Luo receives a $500,000 annual base salary and a $150,000 target bonus, while Eastling receives $339,066 and a $70,000 target bonus, with at-will terms and enhanced change-of-control provisions.MarketBeatGyre Therapeutics (NASDAQ:GYRE) Stock Rating Cut to Sell at Wall Street ZenWall Street Zen downgraded Gyre Therapeutics from hold to sell, citing a Q2 EPS miss of $0.06 versus consensus. The company reported $29.11M revenue and a negative return on equity of 6.57%. Analysts forecast a -0.61 EPS for the current year.American Banking and Market NewsGyre Therapeutics (NASDAQ:GYRE) Downgraded by Wall Street Zen to “Sell”Wall Street Zen downgraded Gyre Therapeutics to 'sell' from 'hold' on Saturday. The company reported Q2 EPS of -$0.12, missing the -$0.06 consensus, with revenue of $29.11 million. Analysts expect -$0.61 EPS for the fiscal year.Markets DailyGSK (NYSE:GSK) versus Gyre Therapeutics (NASDAQ:GYRE) Financial ContrastGSK and Gyre Therapeutics are compared across earnings, valuation, profitability, and institutional ownership. GSK beats Gyre on 11 of 14 factors, with higher revenue and earnings, while Gyre trades at a lower P/E ratio. Analysts favor GSK with a consensus price target of $55.33.